- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.05. | Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026 | 2 | GlobeNewswire (USA) | ||
| 21.04. | Journey Medical Corp - 8-K, Current Report | - | SEC Filings | ||
| 21.04. | Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi | 2 | GlobeNewswire (USA) | ||
| 26.03. | Journey Medical stock rating reiterated at Buy by H.C. Wainwright | 4 | Investing.com | ||
| 26.03. | Journey Medical targets expanded Emrosi coverage and EBITDA growth through 2026 amid robust prescription demand | 2 | Seeking Alpha | ||
| JOURNEY MEDICAL Aktie jetzt für 0€ handeln | |||||
| 25.03. | Journey Medical Non-GAAP EPS of $0.10, revenue of $61.6M misses by $3.05M | 1 | Seeking Alpha | ||
| 25.03. | Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights | 310 | GlobeNewswire (Europe) | Total revenues were $61.9 million in FY2025 compared to $56.1 million in FY2024 Emrosi generated net revenues of $14.7 million during the full-year period after its launch in early April 2025 Approximately... ► Artikel lesen | |
| 25.03. | Journey Medical Corp - 8-K, Current Report | 4 | SEC Filings | ||
| 18.03. | Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026 | 2 | GlobeNewswire (USA) | ||
| 04.02. | B.Riley reiterates Buy rating on Journey Medical stock, maintains $12 target | 2 | Investing.com | ||
| 08.01. | Journey Medical (DERM) Publishes Positive Emrosi Phase 1 Microbiome Data | 2 | Insider Monkey | ||
| 10.12.25 | Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology | 3 | GlobeNewswire (USA) | ||
| 12.11.25 | Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights | 289 | GlobeNewswire (Europe) | Third quarter 2025 net revenues were $17.6 million Emrosi total prescriptions increased 146% over the second quarter of 2025 Emrosi net revenues were $4.9 million Company to hold conference call today... ► Artikel lesen | |
| 12.08.25 | Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights | 666 | GlobeNewswire (Europe) | Second quarter 2025 revenues were $15.0 million Emrosi net sales of $2.8 million generated in first full quarter on the market The Company joined the Russell 2000® and Russell 3000® Indexes in June... ► Artikel lesen | |
| 14.05.25 | Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights | 208 | GlobeNewswire (Europe) | Revenue for the First Quarter Ended March 31, 2025 was $13.1 million Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules) Commercial Launch Off to a Strong Start, Initial Prescriptions... ► Artikel lesen |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 22,055 | +0,02 % | JEFFERIES stuft PFIZER INC auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat Pfizer mit einem Kursziel von 35 US-Dollar auf "Buy" belassen. Der Pharmakonzern habe im ersten Quartal positiv überrascht und die Jahresziele... ► Artikel lesen | |
| GILEAD SCIENCES | 114,96 | 0,00 % | Gilead: Erwartungen übertroffen - darum fällt die Aktie trotzdem | Die Biotech-Gesellschaft Gilead Sciences hat am Donnerstagabend nach US-Börsenschluss die Zahlen für das erste Quartal des neuen Geschäftsjahres veröffentlicht. Trotz besser als erwarteter Vorgaben... ► Artikel lesen | |
| ELI LILLY | 846,20 | +0,34 % | Wegovy treibt die Milliarden: Novo-Aktie haussiert - aber Eli Lilly nimmt dem Konzern gerade den Markt weg | © Foto: Richard Drew - APStarke Quartalszahlen treffen auf brutalen Wettbewerb. Während Novo auf Wegovy setzt, zieht Lilly nach. Für Anleger geht es jetzt um Timing - ist das der Turnaround oder der... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 383,40 | +0,39 % | Vertex Pharmaceuticals Incorporated: Vertex Announces CASGEVY Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany | -The agreement ensures sustainable access to this innovative therapy for eligible patients ages 12 years and older in Germany- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today... ► Artikel lesen | |
| EYEPOINT | 11,500 | -1,71 % | EyePoint, Inc.: EyePoint Reports First Quarter 2026 Financial Results and Highlights Recent Corporate Developments | Phase 3 wet AMD trials, LUGANO and LUCIA, remain on track with topline data expected beginning mid-2026 -Phase 3 DME clinical trials, COMO and CAPRI, rapidly advancing with over one-third of patients... ► Artikel lesen | |
| LIGAND PHARMACEUTICALS | 182,00 | -4,21 % | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement | $15 million payment fulfills previously scheduled tranche under royalty-based financing agreement, bringing total capital received from Ligand to $40 million to date in exchange for tiered royalty... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 196,90 | +1,47 % | Jazz Pharmaceuticals plc: Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences | DUBLIN, May 12, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that company management will participate in fireside chats at the following investor conferences:
2026... ► Artikel lesen | |
| OPKO HEALTH | 0,920 | -1,60 % | OPKO Health, Inc.: OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results | MIAMI, April 28, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three months ended March 31, 2026. Highlights from the first... ► Artikel lesen | |
| UNITED THERAPEUTICS | 492,20 | +2,35 % | United Therapeutics Corp Q1 Income Declines | WASHINGTON (dpa-AFX) - United Therapeutics Corp (UTHR) released a profit for first quarter that Dropped, from last yearThe company's bottom line came in at $274.9 million, or $5.82 per share.... ► Artikel lesen | |
| ROYALTY PHARMA | 43,855 | -2,54 % | Royalty Pharma Q1 Profit, Revenue Increase; Raises Full-year Portfolio Receipts Outlook | WASHINGTON (dpa-AFX) - Royalty Pharma plc (RPRX) on Thursday reported higher first-quarter earnings, supported mainly by growth in income from financial royalty assets.Net income before tax... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 26,500 | -0,38 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results | Delivered Q1 2026 Total Revenues of $149.4 MillionResults include 28% YoY Increase in Net Product Revenues from FIRDAPSE® & AGAMREE® Reported Cash and Cash Equivalents of $755.9 Million and No Funded... ► Artikel lesen | |
| BRIDGEBIO PHARMA | 56,85 | +1,23 % | BridgeBio Pharma, Inc.: BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1 | - Phase 3 CALIBRATE primary results were presented in an oral presentation at the 2026 ECE, demonstrating the rapid and durable benefit of encaleret across key clinical parameters in ADH1 - All pre-specified... ► Artikel lesen | |
| TG THERAPEUTICS | 36,600 | +0,83 % | TG THERAPEUTICS, INC. - 10-Q, Quarterly Report | ||
| CORBUS PHARMACEUTICALS | 9,930 | +1,85 % | Corbus Pharmaceuticals Holdings, Inc.: Corbus Pharmaceuticals Reports Q1 2026 Financial Results and Provides a Corporate Update | Reached broad alignment with the FDA on the registration path for CRB-701 for 2L treatment in head and neck squamous cell carcinoma (HNSCC) and cervical cancer with CRB-701Announced presentation of... ► Artikel lesen | |
| AYTU BIOPHARMA | 1,570 | -100,00 % | Aytu BioPharma, Inc.: Aytu BioPharma to Report Fiscal 2026 Third Quarter Operational and Financial Results on May 13, 2026 | DENVER, CO / ACCESS Newswire / May 6, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous... ► Artikel lesen |
Das Unternehmen JOURNEY MEDICAL CORPORATION kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 5,030 Euro und damit +0,40 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu JOURNEY MEDICAL CORPORATION finden Sie auf Wallstreet Online.